Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Belviso

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
American Journal of Epidemiology|October 6, 2021
Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and SimulationNicholas Belviso, Yichi Zhang, Herbert D Aronow, et al.
Drugs - Real World Outcomes|May 29, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with NatalizumabKaren Blitz-Shabbir, Aimee M Banks, Hina Garg, et al.
Advances in Therapy|May 19, 2026
Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database AnalysisPeiqing Qian, Jenna Brunn, Wennifer Giglio, et al.
Journal of Comparative Effectiveness Research|February 12, 2025
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims databaseAliza B Ben-Zacharia, Jenny J Feng, Brandon P Moss, et al.
Neurology and Therapy|April 15, 2023
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE StudiesLilyana Amezcua, Yang Mao-Draayer, Wendy S Vargas, et al.
Neurology|February 20, 2025
Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005)Sophia Woodson, Edward Gettings, Chu-Yueh Guo, et al.
Multiple Sclerosis and Related Disorders|July 3, 2024
Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosisRiley Bove, Angela Applebee, Katrina Bawden, et al.
Neurology and Therapy|December 14, 2024
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM StudyKrupa Shah Pandey, Kathryn Giles, Konstantin Balashov, et al.
Advances in Therapy|April 30, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse OutcomesDaniel Bandari, Devon Conway, Liang Dong, et al.
Neurology and Therapy|June 16, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USASophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
American Journal of Epidemiology|October 6, 2021
Addressing Posttreatment Selection Bias in Comparative Effectiveness Research, Using Real-World Data and SimulationNicholas Belviso, Yichi Zhang, Herbert D Aronow, et al.
Drugs - Real World Outcomes|May 29, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White Patients with Multiple Sclerosis Treated with NatalizumabKaren Blitz-Shabbir, Aimee M Banks, Hina Garg, et al.
Advances in Therapy|May 19, 2026
Evaluation of Documented Infections by Provider Specialty in Patients with Multiple Sclerosis Receiving Disease-Modifying Therapies: A Claims Database AnalysisPeiqing Qian, Jenna Brunn, Wennifer Giglio, et al.
Journal of Comparative Effectiveness Research|February 12, 2025
Clinical characteristics and treatment outcomes in multiple sclerosis patients treated with anti-CD20s who switched to fumarates: a retrospective analysis of a US healthcare claims databaseAliza B Ben-Zacharia, Jenny J Feng, Brandon P Moss, et al.
Neurology and Therapy|April 15, 2023
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE StudiesLilyana Amezcua, Yang Mao-Draayer, Wendy S Vargas, et al.
Neurology|February 20, 2025
Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005)Sophia Woodson, Edward Gettings, Chu-Yueh Guo, et al.
Multiple Sclerosis and Related Disorders|July 3, 2024
Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosisRiley Bove, Angela Applebee, Katrina Bawden, et al.
Neurology and Therapy|December 14, 2024
Long-Term Safety and Effectiveness of Dimethyl Fumarate in Patients with Multiple Sclerosis Treated in Routine Medical Practice: Final Analysis of the ESTEEM StudyKrupa Shah Pandey, Kathryn Giles, Konstantin Balashov, et al.
Advances in Therapy|April 30, 2026
Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse OutcomesDaniel Bandari, Devon Conway, Liang Dong, et al.
Neurology and Therapy|June 16, 2025
Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USASophia Woodson, Edward J Gettings, Chu-Yueh Guo, et al.
Pageof 3